Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ)
CNY 18.81
(0.16%)
CNY 18.81
(0.16%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 663.02 Million | 514.91 Million | 540.62 Million | 592.92 Million | 660.01 Million | 517.14 Million |
| Cost of Revenue | 396.67 Million | 366.21 Million | 357.12 Million | 298.53 Million | 319.22 Million | 295.62 Million |
| Gross Profit | 266.35 Million | 148.69 Million | 183.5 Million | 294.38 Million | 340.79 Million | 221.51 Million |
| Operating Expenses | 60.13 Million | 66.95 Million | 52.23 Million | 91.1 Million | 127.06 Million | 107.91 Million |
| Selling, General and Administrative Expenses | 31.99 Million | 23.77 Million | 21.53 Million | 1.15 Million | 17.42 Million | 1.09 Million |
| Research and Development Expenses | 52.77 Million | 19.84 Million | 18.28 Million | 22.97 Million | 24.99 Million | 20.87 Million |
| Other Expenses | -54.01 Million | -1.28 Million | -102.28 Thousand | 28.16 Million | 2.73 Million | 17.81 Million |
| Cost and Expenses | 457.69 Million | 433.17 Million | 409.35 Million | 389.64 Million | 446.29 Million | 403.54 Million |
| Operating Income | 205.33 Million | 148.72 Million | 139.28 Million | 198.96 Million | 218.1 Million | 107.44 Million |
| Interest Expense | 576.27 Thousand | 344.41 Thousand | 372.56 Thousand | 9.12 Million | 19.59 Million | 32.25 Million |
| Income Tax Expense | 26.69 Million | 21.71 Million | 17.53 Million | 30.55 Million | 32.37 Million | 15.14 Million |
| Earnings before Tax | 202.81 Million | 147.44 Million | 139.18 Million | 198.63 Million | 216.99 Million | 106.62 Million |
| Net Income | 176.11 Million | 125.79 Million | 121.64 Million | 168.07 Million | 100.28 Million | 47.73 Million |
| Earnings Per Share Basic | 0.61 | 0.44 | 0.42 | 0.58 | 0.35 | 0.22 |
| Earnings Per Share Diluted | 0.61 | 0.44 | 0.42 | 0.58 | 0.35 | 0.22 |
| Weighted Average Shares Outstanding | 288.71 Million | 288 Million | 288 Million | 288 Million | 288 Million | 212.15 Million |
| Weighted Average Shares Outstanding (Diluted) | 288.71 Million | 288 Million | 288 Million | 288 Million | 288 Million | 212.15 Million |
| Gross Margin | 0.40 | 0.29 | 0.34 | 0.50 | 0.52 | 0.43 |
| EBIT Margin | 0.34 | 0.33 | 0.30 | 0.37 | 0.39 | 0.33 |
| Profit Margin | 0.27 | 0.24 | 0.23 | 0.28 | 0.15 | 0.09 |
| EBITDA | 225.15 Million | 169.77 Million | 158.92 Million | 219.33 Million | 236.82 Million | 129.61 Million |
| Earnings Before Tax Margin | 0.31 | 0.29 | 0.26 | 0.34 | 0.33 | 0.21 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 92.12 Million | 102.17 Million | 137.48 Million | 657.11 Million | 119.13 Million | 136.68 Million |
| Cost of Revenue | 78.23 Million | 70.34 Million | 85.71 Million | 402.29 Million | 76.65 Million | 75.54 Million |
| Gross Profit | 13.89 Million | 31.83 Million | 51.77 Million | 254.81 Million | 42.47 Million | 61.14 Million |
| Operating Expenses | 22.26 Million | 21.52 Million | 26.75 Million | 109.47 Million | 24.44 Million | 35.58 Million |
| Selling, General and Administrative Expenses | 32.14 Million | 13.6 Million | 15.8 Million | - | 8.85 Million | 33.57 Million |
| Research and Development Expenses | 6.97 Million | 7.91 Million | 10.94 Million | - | 17.11 Million | 14.71 Million |
| Other Expenses | -16.85 Million | -227.42 Thousand | -17.17 Thousand | 51.16 Thousand | 1.52 Million | -236.25 Thousand |
| Cost and Expenses | 100.49 Million | 91.86 Million | 112.46 Million | 511.77 Million | 101.1 Million | 111.12 Million |
| Operating Income | 1.82 Million | 10.31 Million | 25.01 Million | 145.33 Million | 18.02 Million | 37.37 Million |
| Interest Expense | 57.99 Thousand | 61.8 Thousand | 63.25 Thousand | 307.43 Thousand | 103.77 Thousand | 70.27 Thousand |
| Income Tax Expense | -4.47 Million | 5.44 Million | 6.94 Million | 26.69 Million | 428.33 Thousand | 5.66 Million |
| Earnings before Tax | 1.69 Million | 36.56 Million | 44.32 Million | 202.81 Million | 32.02 Million | 37.14 Million |
| Net Income | 6.16 Million | 31.11 Million | 37.38 Million | 176.11 Million | 31.6 Million | 31.47 Million |
| Earnings Per Share Basic | 0.02 | 0.11 | 0.13 | - | 0.11 | 0.11 |
| Earnings Per Share Diluted | 0.02 | 0.11 | 0.13 | - | 0.11 | 0.11 |
| Weighted Average Shares Outstanding | 288 Million | 288 Million | 288 Million | 288 Million | 288 Million | 288 Million |
| Weighted Average Shares Outstanding (Diluted) | 288 Million | 288 Million | 288 Million | 288 Million | 288 Million | 288 Million |
| Gross Margin | 0.15 | 0.31 | 0.38 | 0.39 | 0.36 | 0.45 |
| EBIT Margin | 0.02 | 0.15 | 0.32 | - | 0.20 | 0.27 |
| Profit Margin | 0.07 | 0.30 | 0.27 | 0.27 | 0.27 | 0.23 |
| EBITDA | 1.75 Million | 15.65 Million | 43.76 Million | - | 23.39 Million | 36.48 Million |
| Earnings Before Tax Margin | 0.02 | 0.10 | 0.18 | 0.22 | 0.15 | 0.27 |
FBU
ONPH
S32
300762
3013
ERO